FierceBiotechOriginal article
{"a":[{"_":"GSK cuts losses on $700M upfront Alzheimer’s collab with Alector following 2 clinical failures","$":{"href":"/biotech/gsk-cuts-losses-700m-upfront-alzheimers-collab-alector-following-two-clinical-failures","hreflang":"en"}}]}
PartnershipnegativeNegative
AI Analysis
Summary
GSK has terminated its $2.2 billion neurodegenerative disease collaboration with Alector after both 'next generation' drug candidates failed in clinical trials, cutting the company's losses on the deal.
Clinical Trial Data
Primary Endpoint
Not Met
Outcome Details
GSK terminated $2.2 billion neurodegenerative disease collaboration with Alector following clinical failures of two 'next generation' drugs
Importance:7/10
Sentiment:
-0.90
partnership terminationclinical failuresAlzheimer's diseaseneurodegenerative diseasedeal collapse
Read the original article
Published by FierceBiotech on July 9, 2026 2:50 AM